Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) EBITDA Margin (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed EBITDA Margin for 2 consecutive years, with 291.68% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 42989.0% to 291.68% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 819.81% through Dec 2025, up 99963.0% year-over-year, with the annual reading at 819.81% for FY2025, 99963.0% up from the prior year.
  • EBITDA Margin hit 291.68% in Q4 2025 for Prelude Therapeutics, up from 303.42% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 291.68% in Q4 2025 to a low of 1060.47% in Q3 2024.